News Search Results
Feb 22, 2026, 19:10 ET CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
progressed following concurrent or sequential platinum-based CRT;For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma;In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent
More news about: CStone Pharmaceuticals
Feb 20, 2026, 16:00 ET Nachawati Law Group Supports $7.25B Settlement Class-Action to Resolve Roundup Cancer Litigation
Feb. 20, 2026 /PRNewswire/ -- Nachawati Law Group, which represents more than 4,200 individuals who have developed non-Hodgkin lymphoma following exposure to Monsanto's Roundup herbicide, today expressed support for a recently announced $7.25 billion class-action settlement framework.
More news about: Nachawati Law Group
Feb 20, 2026, 02:00 ET U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
VENCLEXTA® (venetoclax) VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis.
More news about: AbbVie
Feb 19, 2026, 16:01 ET Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
trial's follow up period by 6-12 months.*The 12 cancer types include anus, bladder, colorectal, esophagus, head and neck, liver/bile duct, lung, lymphoma, myeloma/plasma cell neoplasm, ovary, pancreas, stomach.About the NHS-Galleri Trial (NCT05611632; ISRCTN91431511)The NHS-Galleri
More news about: GRAIL, Inc.
Feb 19, 2026, 12:06 ET Waters Kraus Paul & Siegel Teams with Coalition of Law Firms to Reach $7.25 Billion Monsanto Roundup Settlement Class-Action
settlement class-action with Monsanto. The settlement would resolve thousands of existing and future claims for people diagnosed with non-Hodgkin Lymphoma (NHL) after exposure to Monsanto's Roundup herbicide. Several large jury verdicts have linked the glyphosate-based herbicide to NHL, a type
More news about: Waters Kraus Paul & Siegel
Feb 18, 2026, 11:16 ET Astaxanthin Market to Reach $1.6 Billion, Globally, by 2033 at 8.1% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/microbiome-sequencing-market-A13576 Lymphoma Therapeutics Market - https://www.alliedmarketresearch.com/lymphoma-therapeutics-market Ultrasound Devices Market -
More news about: Allied Market Research
Feb 17, 2026, 13:02 ET HOLLAND LAW FIRM ANNOUNCES MONSANTO AGREEMENT TO PAY UP TO $7.25 BILLION IN NATIONWIDE SETTLEMENT TO COMPENSATE THOSE DIAGNOSED WITH NON-HODGKIN LYMPHOMA FROM ROUNDUP WEEDKILLER EXPOSURE
the filing of a $7.25 billion proposed nationwide class-action settlement resolving claims that exposure to Roundup herbicides caused non-Hodgkin lymphoma (NHL) in the 22nd Judicial Circuit Court for the City of St. Louis, Missouri. Funded by Monsanto, Roundup's manufacturer, the settlement
More news about: Holland Law Firm
Feb 17, 2026, 11:25 ET /C O R R E C T I O N -- BLOOD CANCER UNITED, INC./
WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, will officially launch its 2026
More news about: BLOOD CANCER UNITED, INC.
Feb 17, 2026, 11:25 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
its off-the-shelf CD19 CAR-NK cell therapy with ANKTIVA (nogapendekin alfa inbakicept) and rituximab in patients with indolent B-cell non-Hodgkin lymphoma (NHL), including Waldenström's Macroglobulinemia. The trial builds on Phase 1 QUILT-106 results in which all four evaluable patients with Waldenström's
More news about: Equity Insider
Feb 17, 2026, 11:17 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
its off-the-shelf CD19 CAR-NK cell therapy with ANKTIVA (nogapendekin alfa inbakicept) and rituximab in patients with indolent B-cell non-Hodgkin lymphoma (NHL), including Waldenström's Macroglobulinemia. The trial builds on Phase 1 QUILT-106 results in which all four evaluable patients with Waldenström's
More news about: Equity Insider
Feb 17, 2026, 10:02 ET The Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients
Ahmad, in collaboration with Medical City Fort Worth Hospital, are treating The Center's first patient with CAR-T, a 62-year-old Bowie man with B-Cell Lymphoma.As one of the first independent practices to deliver this innovative therapy outside of a hospital in Texas, the Center's program marks a milestone
More news about: The Center for Cancer and Blood Disorders
Feb 17, 2026, 09:00 ET Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity
life-threatening toxicity of CAR T-cell therapy. Despite the transformative efficacy of CAR T-cell treatments for large B-cell lymphoma (LBCL), mantle cell lymphoma, follicular lymphoma, and B-cell acute lymphoblastic leukemia, the biological drivers of neurotoxicity have remained poorly understood."This
More news about: Metabolon, Inc.
Feb 17, 2026, 09:00 ET Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity
life-threatening toxicity of CAR T-cell therapy. Despite the transformative efficacy of CAR T-cell treatments for large B-cell lymphoma (LBCL), mantle cell lymphoma, follicular lymphoma, and B-cell acute lymphoblastic leukemia, the biological drivers of neurotoxicity have remained poorly understood."This
More news about: Metabolon, Inc.
Feb 17, 2026, 08:52 ET AskAriel.com Launches Redesigned Website Offering Natural Support For Pets With Chronic Health Problems
quality of life.Dog owners will also find expanded condition-based resources. The site includes updated guidance for supporting dogs with lymphoma, collapsed trachea, inflammatory bowel disease, yeast issues, and chronic skin problems. Each section brings together supplement information and feeding
More news about: AskAriel.com
Feb 17, 2026, 08:30 ET Accord Healthcare Launches Lenalidomide Capsules, Expanding Access to Essential Oncology Therapies
Lenalidomide is an oral immunomodulatory agent widely used in the treatment of multiple myeloma, mantle cell lymphoma, and non-Hodgkins Lymphoma. The launch of Accord's Lenalidomide Capsules provides increased patient access in a complex oncology treatment landscape."Access
More news about: Accord Healthcare US
Feb 16, 2026, 10:15 ET CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
(CLL) or small lymphocytic lymphoma (SLL). Building on the initial success of CD19 CAR T-cell therapies in treating acute lymphoblastic leukemia (ALL) and large B-cell lymphoma, research into adult leukemias has advanced. This broadening of indications for mantle cell lymphoma (MCL) and other hematologic
More news about: MarketsandMarkets
Feb 13, 2026, 08:00 ET Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
international markets, and the potential to build a durable oncology franchise. Most importantly, LYMPHIR now offers patients living with cutaneous T-cell lymphoma a meaningful new treatment option and a more hopeful future," added Mazur."We remain committed to financial stewardship to sustain this momentum,
More news about: Citius Pharmaceuticals, Inc.
Feb 13, 2026, 08:00 ET Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
oncology company with an FDA-approved IL-2 receptor-directed immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy;Established nationwide specialty distribution infrastructure, completing initial distributor
More news about: Citius Oncology, Inc.
Feb 12, 2026, 17:31 ET BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
Non-Hodgkin's Lymphoma MarketNon-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease,
More news about: DelveInsight Business Research, LLP
Feb 12, 2026, 07:30 ET Soligenix Details Recent Progress and Upcoming Milestones
HyBryte™ (SGX301 or synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (CTCL) are expected in the second half of 2026, with an interim analysis fast approaching in 2Q. Patient enrollment continues to progress nicely with
More news about: SOLIGENIX, INC.
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory
More news about: Karyopharm Therapeutics Inc.
Feb 11, 2026, 08:00 ET Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
in the U.S. in December 2025.About Cutaneous T-cell LymphomaCutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the
More news about: Citius Oncology, Inc.
Feb 06, 2026, 08:15 ET Marriott foundations give $100 million to Mayo Clinic for healthcare transformation
Clinic.Today, Mrs. Debbie Marriott Harrison also credits Mayo Clinic for lifesaving care as an adult, as she has faced thyroid cancer and lymphoma. Through these and other experiences, the family continues to support the institution's vision for patient-centered care.Bill Marriott served
More news about: Mayo Clinic
Feb 05, 2026, 09:00 ET Next Level Performance Highlights a Year of Community Impact and Charitable Engagement in 2025
FoodBank of New Jersey (including monetary support and Women Fighting Hunger Luncheon sponsorship)Lady Dukes FoundationLeukemia and Lymphoma Society (Little Heroes Prom sponsor)Noah's Ark Animal WorkshopBarnabas Children's HospitalAnchor HouseWreaths
More news about: Next Level Performance
Feb 05, 2026, 07:30 ET Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.